Monitoring Agency Report for the Quarter ended on March 31, 2026.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anlon Healthcare submitted its Q4 FY2026 monitoring report (IPO in August 2025, raise of Rs 12,103 lakh). CRISIL Ratings confirmed full utilization of net proceeds across all objects: Rs 3,072 lakh for capex/expansion fully deployed, Rs 500 lakh for debt repayment fully utilized, Rs 4,315 lakh for working capital fully used, and Rs 2,774 lakh of Rs 2,787 lakh general corporate funds deployed (Rs 13.20 lakh remains). The company completed two acquisitions using IPO proceeds — Bizotic Life Science (Rs 379.69 lakh) and Apiqo Organics (Rs 540.06 lakh). Actual issue expenses came in Rs 84.39 lakh lower than estimated, with savings reallocated to general corporate purposes. A shareholder-approved expansion of IPO objects (January 2026) enabled inorganic growth beyond the original manufacturing facility expansion scope. No implementation delays reported.
IPO proceeds are being deployed as intended with both organic and inorganic growth initiatives underway; the fully drawn debt repayment reduces financial burden and improves balance sheet visibility for shareholders.